Investigators used the company’s investigational Aveir conduction system pacing (CSP) leadless pacemaker as part of a feasibility study. The procedures mark the first implants of a leadless pacemaker in the left bundle branch area. Abbott says it could mimic the heart’s natural beat, providing a potential new treatment for people with slower-than-normal heart rhythms.
The procedures took place as part of the prospective Leadless CSP feasibility study. It evaluates the safety and performance of Aveir CSP. Dr. Petr Neužil, head of cardiology at Na Homolce Hospital in Prague, Czech Republic, and the site’s principal investigator, completed the procedures earlier this fall along with Mount Sinai Hospital’s Dr. Vivek Y. Reddy, the study’s principal investigator.
CSP is a technique in which a traditional pacemaker is implanted deep into the wall. This separates the heart’s left and right chambers. In turn, this activates the left bundle branch area, enabling physiological pacing to mimic the heart’s natural electrical current.
Integrating CSP procedures with leadless pacemaker technology could deliver unique benefits, Abbott says. Leadless systems eliminate the need for cardiac leads and an implanted pulse generator. That helps avoid the risks of lead- and pocket-related complications.
Abbott has FDA breakthrough device designation for its Aveir CSP leadless system.
“Bringing our proven leadless pacemaker technology to the left bundle branch area has great potential to be another transformative moment in cardiac care,” said Randel Woodgrift, SVP of Abbott’s cardiac rhythm management business. “By continuously innovating our approach to pacing, Abbott is revolutionizing care for millions of people living with slow or irregular heart rhythms.”
